A Phase 3, Multicenter, Randomized, Double-Blind Noninferiority Study of Oral Solithromycin Compared to Oral Azithromycin in the Treatment of Patients with Community-Acquired Pneumonia
Latest Information Update: 18 Jan 2023
At a glance
- Drugs Solithromycin (Primary) ; Azithromycin
- Indications Community-acquired pneumonia
- Focus Registrational; Therapeutic Use
- Sponsors FUJIFILM Toyama Chemical
- 16 Jan 2023 Planned End Date changed from 31 Mar 2023 to 30 Sep 2023.
- 03 Aug 2022 The study protocol amended to change minimum age of study inclusion from 20 years to 18 years.
- 17 Dec 2021 New trial record